Archive: Company News
Dopavision Reports Successful Completion of Enrollment for MyopiaX-1 Trial
– MyopiaX-1 trial to generate first clinical evidence with MyopiaX®, a novel therapeutic approach to manage myopia progression
– First data readout expected in Q1/ 2024 with study completion planned for September 2024
Dopavision, a clinical-stage company developing innovative solutions for the management of myopia, today announced the successful completion of enrollment in its MyopiaX-1 trial (NCT04967287). MyopiaX-1 is a randomized, active-controlled trial to evaluate the safety, tolerability, and clinical outcomes of MyopiaX® in pediatric participants with myopia. Read more…